U.S. Entertainment Stock News

Wondering if AppLovin's current share price reflects its true worth, or if the market is mispricing the story. The stock recently closed at US$442.39, with returns of 5.7% over 30 days, a 28.5% decline year to date, and 40.9% over the last year, alongside a very large 3 year return. Recent coverage has focused on AppLovin's position within software and digital advertising, as investors reassess how its platform fits into the broader app monetization ecosystem. That context helps explain why...

Apple secured a favorable U.S. trade ruling that allows continued sales of its latest Apple Watch models, easing concerns about a potential import ban linked to patent disputes. In China, Apple reduced its App Store commission rate from 30% to 25% in response to regulatory pressure on app platform fees. CEO Tim Cook publicly addressed and dismissed speculation about his retirement, aiming to calm questions around leadership continuity. For investors watching NasdaqGS:AAPL, these...

For readers wondering whether Valero Energy at around US$239.86 still offers value or if the easy gains are gone, this article breaks down what the current price might really be telling you. Recent share price moves have been strong, with returns of 4.0% over 7 days, 19.5% over 30 days, 45.1% year to date, 87.8% over 1 year, 103.2% over 3 years, and 290.1% over 5 years. Recent news around Valero Energy has focused on broad sector attention, capital allocation themes, and how large refiners...

SWK Holdings (SWKH) closed out FY 2025 with fourth quarter revenue of US$6.6 million and a basic EPS loss of US$1.60, compared with revenue of US$9.2 million and basic EPS of US$0.48 in the same quarter a year earlier. The trailing twelve month EPS came in at a loss of US$0.21 on revenue of US$37.6 million. Over recent quarters, revenue has moved from US$9.2 million in Q4 2024 to US$12.2 million in Q1 2025, US$8.1 million in Q2 2025 and US$10.6 million in Q3 2025. Basic EPS shifted from...

Textron (TXT) is back on investors’ radar after a recent move in its share price, with the stock roughly flat over the past day but showing mixed returns over the past week, month and past 3 months. See our latest analysis for Textron. Looking beyond the latest move, Textron’s share price has softened over the past month, with a 30 day share price return of an 11.91% decline, yet its 1 year total shareholder return of 21.58% points to longer term momentum that remains positive overall. If...

In its latest quarter, First Interstate BancSystem reported earnings per share ahead of analyst expectations but revenue below forecasts, alongside improving net interest margin and lower non‑performing assets. The company also expanded its share repurchase authorization, signaling management’s confidence in its capital position and balance sheet resilience. Next, we’ll examine how the expanded share repurchase authorization may influence First Interstate BancSystem’s broader investment...

Janus Henderson Group (NYSE:JHG) is back on investor screens after a recent move in its share price, with the stock closing at $50.43. This has prompted a closer look at its recent return profile. See our latest analysis for Janus Henderson Group. The recent pullback, with a 1-day share price return of a 1.83% decline, comes after a steadier backdrop that includes a 90-day share price return of 6.28% and a 1-year total shareholder return of 39.00%. This suggests that momentum has been...

Marqeta (MQ) is drawing attention after recent trading left the stock at US$4.08, with a 1 day return of 3.8% and mixed performance over the month and the past 3 months. See our latest analysis for Marqeta. That 3.8% 1 day share price return comes after a weaker run, with the 30 day share price return of 3.8% and the year to date share price return of 12.1% both well behind the 3 year total shareholder return of 14.3%. This suggests recent momentum has faded even though longer term holders...

Wondering whether GeneDx Holdings at around US$69.84 is a bargain or already pricing in a lot of optimism? This article walks through what the numbers currently say about value. The stock has had a choppy run, with a 10.2% decline over the last 7 days, a 14.9% decline over the last 30 days, a 47.2% decline year to date, a very large 3 year return, and a 33.1% decline over the last year. These swings have kept GeneDx on the radar for investors watching for changing expectations and risk...

Wondering whether CRISPR Therapeutics at around US$46.24 is offering good value, or if the recent excitement is already priced in? This breakdown is designed to help you frame that question clearly. The stock is up 12.2% over the past year, even though it shows a 5.1% decline over 7 days, a 13.5% decline over 30 days, and a 14.0% decline year to date. Recent trading has therefore looked quite different to the longer term picture. Recent headlines around CRISPR Therapeutics have focused on...

Nike (NYSE:NKE) is reporting early signs of a turnaround as wholesale revenue shows a rebound. Management is working to repair relationships with wholesale partners, with recent updates pointing to more stable sales trends. These shifts come while consumer demand and broader macroeconomic conditions remain under pressure. Nike operates at the center of global athletic footwear and apparel, where brand reach and product relevance are crucial. Recent weakness in demand, profit headwinds, and...

Event context and recent share performance Merit Medical Systems (MMSI) shares have come under pressure recently, with the stock showing a 2.4% decline over the past day, 4.6% over the past week, and deeper pullbacks over the past month and past 3 months. See our latest analysis for Merit Medical Systems. The recent pullback, including a 30 day share price return of 18.9% decline and a year to date share price return of 22.8% decline, sits alongside a 1 year total shareholder return of 34.4%...

AptarGroup's Unidose Powder Nasal Spray System is being used in ENA Respiratory's Phase II trial for INNA-051. The trial targets prevention of symptomatic viral respiratory infections through a non-vaccine nasal approach. This use case highlights AptarGroup's role in advanced nasal drug delivery technologies within clinical pipelines. AptarGroup (NYSE:ATR) is widely known for drug delivery and consumer dispensing solutions, and this latest trial involvement puts its nasal systems in the...

MDU Resources Group (MDU) has drawn attention after recent trading, with the share price around $19.65 and mixed short term returns, including a 3.7% one day decline and 6.9% drop over the past week. See our latest analysis for MDU Resources Group. That recent 1-day share price return of negative 3.7% and 7-day return of negative 6.9% sit against a much stronger backdrop, with 1-year total shareholder return of 20.8% and 3-year total shareholder return of 93.6%. This suggests long term...

Iovance Biotherapeutics (IOVA) recently outlined its growth plans at the Barclays 28th Annual Global Healthcare Conference, spotlighting early sarcoma data, broader lung and sarcoma ambitions, and upcoming Amtagvi melanoma regulatory decisions in the UK and Australia. See our latest analysis for Iovance Biotherapeutics. At a share price of $3.69, Iovance has given investors a 30 day share price return of 28.57% and a year to date share price return of 46.43%. However, the 5 year total...

Carvana stock moves after recent performance shift Carvana (CVNA) has drawn fresh attention after a recent pullback, with the share price down about 16% over the past month and roughly 35% over the past 3 months. See our latest analysis for Carvana. While the share price has given back ground recently, with a 1-day share price return decline of 4.39% and a 30-day share price return decline of 16.44%, the 1-year total shareholder return of 47.31% and very large 3-year total shareholder return...

Travere Therapeutics (TVTX) has drawn investor attention after recent trading left the shares with a loss of 32.1% year to date, despite a 30.7% total return over the past year. See our latest analysis for Travere Therapeutics. The current share price of US$26.84 sits well below its recent peak, with a 30 day share price return of an 8.4% decline and a year to date share price return of a 32.1% decline. At the same time, the 1 year total shareholder return is 30.7%, suggesting that earlier...

Hadrian and the U.S. Navy have agreed to work together to increase production of submarine parts. The partnership is aimed at supporting U.S. naval shipbuilding capacity and easing supply chain constraints. The move has potential implications for major submarine contractors, including General Dynamics (NYSE:GD). For investors watching General Dynamics at a current share price of $345.78, this new U.S. Navy and Hadrian partnership sits directly in the orbit of the company’s core submarine...

Apollo Global Management (APO) has been in focus after Apollo managed funds agreed to invest US$1.0 billion alongside Realty Income in a joint venture owning roughly 500 single-tenant, long-lease retail properties. See our latest analysis for Apollo Global Management. At a share price of US$112.0, Apollo’s recent 7 day share price return of 7.24% has come after a 90 day share price decline of 24.78%, while its 5 year total shareholder return of 166.66% points to strong longer term...

Alumis reported full-year 2025 results showing US$24.05 million in revenue and a net loss of US$243.33 million, while also filing a universal shelf registration and a US$300 million at-the-market follow-on equity offering alongside positive Phase 3 topline data for its TYK2 inhibitor envudeucitinib in plaque psoriasis. By pairing encouraging late-stage clinical data and plans for a 2026 New Drug Application with expanded financing flexibility, Alumis is signaling a push to advance...

Recent investor commentary has brought fresh attention to HEICO (HEI), after fund managers highlighted its volume growth compared with aerospace peers, continued margin expansion, and strong free cash flow, all tied to supply chain constraints and higher maintenance demand. See our latest analysis for HEICO. Despite HEICO's operational strengths gaining attention, the recent share price tells a different story, with a 1 month share price return of a 21.75% decline and a year to date share...

Sanmina (SANM) is drawing attention after recent share price moves, with the stock showing a 5.7% total return over the past year, along with multi-year gains and weaker performance in the past month. See our latest analysis for Sanmina. The recent 1 month share price decline of 17.0% and 1 day move of 5.7% lower sit in sharp contrast to a 1 year total shareholder return of 56.9%. This suggests longer term momentum while near term sentiment has cooled. If Sanmina's recent swing has you...

If you are wondering whether Intuitive Surgical at around US$477.97 is a bargain or already pricing in high expectations, you are not alone. The stock has returned 1.2% over the last 7 days, after a 5.2% decline over 30 days and a 14.9% decline year to date, while the 1 year return sits at a 2.9% decline and the 3 and 5 year returns are 86.4% and 96.2% respectively. Recent coverage has focused on how Intuitive Surgical fits into longer term themes in medical technology and how sentiment has...

PitchBook, a Morningstar subsidiary, was named one of G2's top-rated financial services software products for 2026, reflecting customer driven ratings. Morningstar (NasdaqGS:MORN) announced the winners of its UK Awards for Investing Excellence, recognising firms and funds for investment research and stewardship in the UK market. For you as an investor, these updates highlight different sides of Morningstar’s business, from software and data through PitchBook to research and ratings under...